Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is seeking a Senior Scientist, DMPK to lead the design and execution of preclinical drug metabolism and pharmacokinetics studies for RNAi therapeutics, manage internal and CRO resources, and deliver IND-enabling data packages. The role involves cross‑functional collaboration with chemists, biologists, and translational scientists to support candidate nomination and regulatory submissions.
Headquarters
Pasadena, California, United States
Company Size
501-1000 employees
Founded
2004
Arrowhead Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers, develops, and delivers RNA interference (RNAi)-based therapeutics to silence disease-causing genes. Using proprietary targeted delivery platforms that enable focused, durable gene knockdown, Arrowhead advances programs across liver and extra‑hepatic indications including cardiometabolic, pulmonary, viral, and rare diseases. The company progresses multiple clinical and preclinical candidates and collaborates with partners to translate RNAi science into new therapies that aim to change how diseases are treated.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Arrowhead Pharmaceuticals.
31% below the average for this role